JKJessica L. Kennedy

Jessica L. Kennedy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jessica L. Kennedy has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Delay or avoidance of routine, urgent and emergency medical care due to concerns about COVID‐19 in a region with low COVID‐19 prevalence: Victoria, Australia

    by Mark É. Czeisler, Jessica L. Kennedy, Joshua F. Wiley, Elise R. Facer‐Childs, Rebecca Robbins, Laura K. Barger, Charles A. Czeisler, Shantha M. W. Rajaratnam, Mark E. Howard


  • Outcomes of non‐cystic fibrosis‐related bronchiectasis post‐lung transplantation

    by Jessica L. Kennedy, Anne Walker, Claire M. Ellender, Kate Steinfort, Catherine Martin, Catherine Smith, Gregory Snell, Helen Whitford

    Background: Lung transplantation is a recognised treatment for end‐stage lung disease due to bronchiectasis. Non‐cystic fibrosis (CF) bronchiectasis and CF are often combined into one cohort; however, outcomes for non‐CF bronchiectasis patients vary between centres, and in comparison with those for CF.Aims: To compare lung transplantation mortality and morbidity of bronchiectasis (non‐CF) patients with those with CF and other indications.Methods: Retrospective analysis of patients undergoing lung transplantation between 1 January 2008 and 31 December 2013. Time to and cause of lung allograft loss was censored on 1 April 2018. A case‐note review was conducted on a subgroup of 78 patients, to analyse hospital admissions as a marker of morbidity.Results: A total of 341 patients underwent lung transplantation; 22 (6%) had bronchiectasis compared with 69 (20%) with CF. The 5‐year survival for the bronchiectasis group was 32%, compared with CF (69%), obstructive lung disease (OLD) (64%), pulmonary hypertension (62%) and ILD (55%) (P = 0.008). Lung allograft loss due to chronic lung allograft dysfunction with predominant infection was significantly higher in the bronchiectasis group at 2 years. The rate of acute admissions was 2.24 higher in the bronchiectasis group when compared with OLD (P = 0.01). Patients with bronchiectasis spent 45.81 days in hospital per person year after transplantation compared with 18.21 days for CF.Conclusions: Bronchiectasis patients in the present study had a lower 5‐year survival and poorer outcomes in comparison with other indications including CF. Bronchiectasis should be considered a separate entity to CF in survival analysis.